The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer.
Gleason score
Predictive factors
Prostate cancer
Prostate-specific antigen
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
13
07
2018
accepted:
10
09
2018
entrez:
4
10
2019
pubmed:
4
10
2019
medline:
4
10
2019
Statut:
ppublish
Résumé
We used a new GP score (Gleason score multiplied by prostate-specific antigen) without the T stage as a predictive value for biochemical failure (BCF) after prostatectomy. We assessed 459 prostate cancer patients who underwent prostatectomies at our institution. Three sub-groups were defined in terms of D'Amico classification risk (low, intermediate, and high) and Gleason score (low, < 50; intermediate, 50-100; and high GP score, > 100). Risk factors for BCF were evaluated by multivariate analysis with a Cox hazard model. A log-rank test was used to compare the BCF rate in the 2 groups. There was nosignificant difference in the non-BCF rate between the lowrisk and low GP score subgroups or the intermediate risk andintermediate GP score subgroups. In contrast, the non-BCFrate of the high GP score subgroup (42.1%) was significantlylower than that of the high-risk subgroup (66.1%, log-rankp = 0.008). Based on multivariate analysis, a high GP score(p = 0.001; HR 3.78; 95%CI 1.95-7.35) was a significant independent risk factor for BCF after prostatectomy. The GP score, consisting of two absolute numbers, may be a valuable predictive factor for BCF after prostatectomy, especially in the high-risk failure group.
Identifiants
pubmed: 31579210
doi: 10.1159/000499298
pii: cur-0013-0025
pmc: PMC6771044
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-30Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Références
J Urol. 2010 Jul;184(1):114-9
pubmed: 20478578
Anticancer Res. 2014 Jun;34(6):3077-81
pubmed: 24922676
J Urol. 2005 Jun;173(6):1938-42
pubmed: 15879786
Jpn J Clin Oncol. 2011 Nov;41(11):1271-6
pubmed: 21971422
Urology. 2014 Dec;84(6):1329-34
pubmed: 25288575
Clin Oncol (R Coll Radiol). 2005 Dec;17(8):655-8
pubmed: 16372494
Cancer Chemother Rep. 1966 Mar;50(3):125-8
pubmed: 5948714
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Cancer. 2002 Jul 15;95(2):281-6
pubmed: 12124827
Strahlenther Onkol. 2007 Sep;183(9):490-6
pubmed: 17762923
Urol Oncol. 2004 Jul-Aug;22(4):295-9
pubmed: 15283886
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):69-75
pubmed: 20594769
Urol Int. 2015;95(4):452-6
pubmed: 26430904
J Urol. 2013 Nov;190(5):1728-34
pubmed: 23680307
Eur Urol. 2014 Jun;65(6):1171-7
pubmed: 23587869
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7
pubmed: 7505775
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):104-9
pubmed: 19286330
Radiother Oncol. 2013 Nov;109(2):211-6
pubmed: 23823866
Urology. 1997 Nov;50(5):733-9
pubmed: 9372884